

Determining a cut-off value for eosinophilic chronic rhinosinusitis*

Chengshuo Wang^{1,2,3}, Luo Zhang^{1,2,3,4}

Rhinology 60: 4, 318 - 319, 2022

<https://doi.org/10.4193/Rhin22.090>

¹ Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, P.R. China

² Beijing Key Laboratory of Nasal Diseases and Beijing Laboratory of allergic diseases, Beijing Institute of Otorhinolaryngology, Beijing, P.R. China

³ Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, P.R. China

⁴ Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, P.R. China

***Received for publication:**

Februari 23, 2021

Accepted: May 4, 2022

Dear Editor:

Classifying eosinophilic chronic rhinosinusitis (eCRS) can be difficult. We read and commented on the article, entitled 'Achieving the best method to classify eosinophilic chronic rhinosinusitis: a systematic review'^(1,2). Toro et al.⁽¹⁾ precisely identified various cut-off values for tissue eosinophilia and emphasised the relevance of clinical parameters, such as recurrence with a low risk of bias. However, Pan and Liu suggested a cut-off value for eosinophilic inflammation based on the distribution of the eosinophil percentage in healthy individuals⁽²⁾. The dilemma involves defining eCRS using either reference intervals (RIs) based on healthy individuals or clinical decision limits (CDLs) based on patients. We provided suggestions from a statistical perspective. The concepts of RIs and CDLs should be distinguished. Also referred to as the 'normal range', RIs are defined as the interval between the two reference limits (2.5th and 97.5th percentiles) obtained from a healthy population with a minimum sample size of 120 (as recommended by the Clinical Laboratory Standards Institute guideline). It answers the question, 'Is the individual healthy?'. Results outside the RIs do not necessarily indicate a disease⁽³⁾. Meanwhile, CDLs are defined as values, resulting from a diagnostic test, that distinguish between two clinical subgroups⁽³⁾. In this case, the test was conducted to classify the patient between eCRS and non-eCRS. It answers the question, 'Is the patient diseased, or is the illness worsening?'⁽³⁾. RIs are based on healthy individuals, while CDLs are based on clinical outcome studies (e.g. prospective cohort studies or meta-analysis), receiver operator characteristic (ROC) curves, guidelines, and consensus values⁽³⁾. Furthermore, the ROC curve is applied when considering the sensitivity and specificity of the diagnostic test.

eCRS refers to an inflammatory phenotype, characterised by the predominance of tissue eosinophils. It is frequently associated with more severe sinus disease as well as worse surgical and medical treatment outcomes. This entity is difficult to treat because of the underlying severe eosinophilic inflammation,

which is quantified using tissue eosinophils (absolute number or percentage) as biomarkers. The diagnosis of eCRS is related to CDLs. Tissue eosinophil levels above the threshold have been associated with a significantly higher risk of adverse clinical outcomes⁽³⁾. Various absolute eosinophil numbers (5–350/high power field (HPF)) and percentages (5–50%) have been used as cut-off values in the diagnostic criteria for eCRS⁽⁴⁾. According to Toro et al., recurrence was the most relevant parameter with a low risk of bias in the classification of eCRS. A cut-off value of 55/HPF was derived from the ROC curve with balanced sensitivity and specificity⁽⁵⁾. This cut-off value was further demonstrated in a meta-analysis⁽⁶⁾. The follow-up time for determining recurrence and postoperative medications have not been standardised. However, recurrence, detected via the routine endoscopic examination, indicates a worse response to treatment. Tissue eosinophilia is characterised by eosinophils, larger than the upper limit of RIs. However, there is insufficient evidence, supporting that a cut-off value as low as 10% is predictive or recurrence. Setting a low threshold (8–10%) harbours the issue of increasing the population of patients diagnosed with eosinophilia and thus administered extensive treatment. Therefore, we recommend using a high outcome-related threshold to define severe eosinophilic inflammation in patients with eCRS. Using a high cut-off value of 55/HPF, the prevalence of eCRS in China and Japan was 50% and 44%, respectively^(5,7). These statistics indicated a decreased discrepancy between countries. In summary, the cut-off values for tissue eosinophils in the diagnosis of eCRS were related to CDLs, rather than RIs. A cut-off value above the threshold was associated with a significantly higher risk of adverse clinical outcomes. Defining eCRS according to clinical parameters, such as recurrence, is important. Based on the approaches for identifying CDLs, more multicentre studies are needed to determine the optimal cut-off values at the national or international level.

Abbreviations

Clinical decision limits (CDLs); Eosinophilic chronic rhinosinusitis (eCRS); High power field (HPF); Receiver operator characteristic (ROC); Reference intervals (RIs).

Acknowledgements

None.

Authorship contribution

CW and LZ were involved in the conception of the paper. LZ wrote the paper.

Conflict of interest

None.

Funding

None.

Ethics approval and consent to participate

Not applicable.

Availability of data and materials

Not applicable.

References

1. Toro MDC, Antonio MA, Alves Dos Reis MG, Assumpcao MS, Sakano E. Achieving the best method to classify eosinophilic chronic rhinosinusitis: a systematic review. *Rhinology* 2021; 59(4): 330-339.
2. Pan L, Liu Z. Classification of eCRS: Based on disease outcome or normal range?: Comment on Toro et al. *Rhinology* 2022; 60(2):159-160.
3. Ozarda Y, Sikaris K, Streichert T, IFCC Committee on Reference intervals and Decision Limits (C-RIDL). Distinguishing reference intervals and clinical decision limits - A review by the IFCC Committee on Reference Intervals and Decision Limits. *Crit Rev Clin Lab Sci* 2018; 55(6): 420-431.
4. Lou H, Zhang N, Bachert C, Zhang L. Highlights of eosinophilic chronic rhinosinusitis with nasal polyps in definition, prognosis, and advancement. *Int Forum Allergy Rhinol* 2018; 8(11): 1218-1225.
5. Lou H, Meng Y, Piao Y, Wang C, Zhang L, Bachert C. Predictive significance of tissue eosinophilia for nasal polyp recurrence in the Chinese population. *Am J Rhinol Allergy* 2015; 29(5): 350-356.
6. McHugh T, Snidvongs K, Xie M, Banglawala S, Sommer D. High tissue eosinophilia as a marker to predict recurrence for eosinophilic chronic rhinosinusitis: a systematic review and meta-analysis. *Int Forum Allergy Rhinol* 2018; 8(12): 1421-1429.
7. Yamada T, Miyabe Y, Ueki S, et al. Eotaxin-3 as a plasma biomarker for mucosal eosinophil infiltration in chronic rhinosinusitis. *Front Immunol* 2019; 10: 74.

Luo Zhang, MD, PhD
Department of Otolaryngology
Head and Neck Surgery
Beijing TongRen Hospital
Capital Medical University.
No. 1, DongJiaoMinXiang
DongCheng District
Beijing 100730
P.R. China

Tel: (+86-10) 6514 1136
Fax: (+86-10) 8511 5988
E-mail: dr.luozhang@139.com